Nintedanib is a small molecule that blocks several signaling pathways involved in lung tissue remodeling. It is classified as an antifibrotic agent used in the management of progressive fibrosing interstitial lung diseases. The drug works by inhibiting tyrosine kinase receptors that drive fibroblast activation and extracellular matrix deposition. By reducing fibroblast proliferation and collagen formation the medication slows disease progression and improves lung function. The inhibition of these pathways alters cellular responses to injury signals and limits the inflammatory cascade that damages alveolar structures. Together these actions collectively modulate the physiological processes that lead to lung scarring and support clinical benefit in affected patients.

Nintedanib is a small molecule tyrosine kinase inhibitor. It is used to treat idiopathic pulmonary fibrosis and certain types of systemic sclerosis interstitial lung disease. The drug works by targeting multiple receptors involved in fibrosis signaling. Specifically it blocks the activity of fibroblast growth factor receptor platelet derived growth factor receptor and vascular endothelial growth factor receptor. By inhibiting these pathways it reduces excessive fibroblast proliferation and extracellular matrix deposition. The result is a slower progression of interstitial lung disease symptoms and improved lung function. Clinical studies have shown that Nintedanib can delay disease worsening compared to placebo. Its pharmacologic effect is achieved through selective inhibition of intracellular kinase domains that mediate pro fibrotic signaling.

The most commonly reported side effects of Nintedanib include diarrhea, nausea and vomiting. Patients may also experience abdominal pain or indigestion as gastrointestinal symptoms. Elevations in liver enzymes can occur, which may be monitored during treatment. Some individuals report headaches, dizziness or fatigue as neurological effects. Skin reactions such as rash or itching have been documented in certain cases. Hypertension and peripheral edema are among the cardiovascular symptoms noted. Laboratory tests may show decreased white blood cell counts in some patients. Most side effects are manageable with dose adjustments or supportive care.

Nintedanib can cause diarrhea nausea and abdominal pain. It may lead to liver enzyme elevations that are detected through routine blood tests. Some patients experience dizziness or headache. Skin reactions such as rash or itching have been reported. The medication can result in decreased appetite and occasional weight loss. Respiratory symptoms like cough or shortness of breath may develop. Fatigue and mild fever have also been observed in clinical studies.